Pharmacological Approaches and Herbal Interventions for Alzheimer's Disease

Lyketsos, C.G.; Carrillo, M.C.; Ryan, J.M.; Khachaturian, A.S.; Trzepacz, P.; Amatniek, J.; Cedarbaum, J.; Brashear, R.; Miller, D.S. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement., 2011, 7(5), 532-539.
[http://dx.doi.org/10.1016/j.jalz.2011.05.2410] [PMID: 21889116]

Srivastava, S.; Ahmad, R.; Khare, S.K. Alzheimer’s disease and its treatment by different approaches: A review. Eur. J. Med. Chem., 2021, 216, 113320.
[http://dx.doi.org/10.1016/j.ejmech.2021.113320] [PMID: 33652356]

Schwarzinger, M.; Dufouil, C. Forecasting the prevalence of dementia. Lancet Public Health, 2022, 7(2), e94-e95.
[http://dx.doi.org/10.1016/S2468-2667(21)00277-2] [PMID: 34998486]

Nichols, E.; Steinmetz, J.D.; Vollset, S.E.; Fukutaki, K.; Chalek, J.; Abd-Allah, F.; Abdoli, A.; Abualhasan, A.; Abu-Gharbieh, E.; Akram, T.T.; Al Hamad, H.; Alahdab, F.; Alanezi, F.M.; Alipour, V.; Almustanyir, S.; Amu, H.; Ansari, I.; Arabloo, J.; Ashraf, T.; Astell-Burt, T.; Ayano, G.; Ayuso-Mateos, J.L.; Baig, A.A.; Barnett, A.; Barrow, A.; Baune, B.T.; Béjot, Y.; Bezabhe, W.M.M.; Bezabih, Y.M.; Bhagavathula, A.S.; Bhaskar, S.; Bhattacharyya, K.; Bijani, A.; Biswas, A.; Bolla, S.R.; Boloor, A.; Brayne, C.; Brenner, H.; Burkart, K.; Burns, R.A.; Cámera, L.A.; Cao, C.; Carvalho, F.; Castro-de-Araujo, L.F.S.; Catalá-López, F.; Cerin, E.; Chavan, P.P.; Cherbuin, N.; Chu, D-T.; Costa, V.M.; Couto, R.A.S.; Dadras, O.; Dai, X.; Dandona, L.; Dandona, R.; De la Cruz-Góngora, V.; Dhamnetiya, D.; Dias da Silva, D.; Diaz, D.; Douiri, A.; Edvardsson, D.; Ekholuenetale, M.; El Sayed, I.; El-Jaafary, S.I.; Eskandari, K.; Eskandarieh, S.; Esmaeilnejad, S.; Fares, J.; Faro, A.; Farooque, U.; Feigin, V.L.; Feng, X.; Fereshtehnejad, S-M.; Fernandes, E.; Ferrara, P.; Filip, I.; Fillit, H.; Fischer, F.; Gaidhane, S.; Galluzzo, L.; Ghashghaee, A.; Ghith, N.; Gialluisi, A.; Gilani, S.A.; Glavan, I-R.; Gnedovskaya, E.V.; Golechha, M.; Gupta, R.; Gupta, V.B.; Gupta, V.K.; Haider, M.R.; Hall, B.J.; Hamidi, S.; Hanif, A.; Hankey, G.J.; Haque, S.; Hartono, R.K.; Hasaballah, A.I.; Hasan, M.T.; Hassan, A.; Hay, S.I.; Hayat, K.; Hegazy, M.I.; Heidari, G.; Heidari-Soureshjani, R.; Herteliu, C.; Househ, M.; Hussain, R.; Hwang, B-F.; Iacoviello, L.; Iavicoli, I.; Ilesanmi, O.S.; Ilic, I.M.; Ilic, M.D.; Irvani, S.S.N.; Iso, H.; Iwagami, M.; Jabbarinejad, R.; Jacob, L.; Jain, V.; Jayapal, S.K.; Jayawardena, R.; Jha, R.P.; Jonas, J.B.; Joseph, N.; Kalani, R.; Kandel, A.; Kandel, H.; Karch, A.; Kasa, A.S.; Kassie, G.M.; Keshavarz, P.; Khan, M.A.B.; Khatib, M.N.; Khoja, T.A.M.; Khubchandani, J.; Kim, M.S.; Kim, Y.J.; Kisa, A.; Kisa, S.; Kivimäki, M.; Koroshetz, W.J.; Koyanagi, A.; Kumar, G.A.; Kumar, M.; Lak, H.M.; Leonardi, M.; Li, B.; Lim, S.S.; Liu, X.; Liu, Y.; Logroscino, G.; Lorkowski, S.; Lucchetti, G.; Lutzky Saute, R.; Magnani, F.G.; Malik, A.A.; Massano, J.; Mehndiratta, M.M.; Menezes, R.G.; Meretoja, A.; Mohajer, B.; Mohamed Ibrahim, N.; Mohammad, Y.; Mohammed, A.; Mokdad, A.H.; Mondello, S.; Moni, M.A.A.; Moniruzzaman, M.; Mossie, T.B.; Nagel, G.; Naveed, M.; Nayak, V.C.; Neupane Kandel, S.; Nguyen, T.H.; Oancea, B.; Otstavnov, N.; Otstavnov, S.S.; Owolabi, M.O.; Panda-Jonas, S.; Pashazadeh Kan, F.; Pasovic, M.; Patel, U.K.; Pathak, M.; Peres, M.F.P.; Perianayagam, A.; Peterson, C.B.; Phillips, M.R.; Pinheiro, M.; Piradov, M.A.; Pond, C.D.; Potashman, M.H.; Pottoo, F.H.; Prada, S.I.; Radfar, A.; Raggi, A.; Rahim, F.; Rahman, M.; Ram, P.; Ranasinghe, P.; Rawaf, D.L.; Rawaf, S.; Rezaei, N.; Rezapour, A.; Robinson, S.R.; Romoli, M.; Roshandel, G.; Sahathevan, R.; Sahebkar, A.; Sahraian, M.A.; Sathian, B.; Sattin, D.; Sawhney, M.; Saylan, M.; Schiavolin, S.; Seylani, A.; Sha, F.; Shaikh, M.A.; Shaji, K.S.; Shannawaz, M.; Shetty, J.K.; Shigematsu, M.; Shin, J.I.; Shiri, R.; Silva, D.A.S.; Silva, J.P.; Silva, R.; Singh, J.A.; Skryabin, V.Y.; Skryabina, A.A.; Smith, A.E.; Soshnikov, S.; Spurlock, E.E.; Stein, D.J.; Sun, J.; Tabarés-Seisdedos, R.; Thakur, B.; Timalsina, B.; Tovani-Palone, M.R.; Tran, B.X.; Tsegaye, G.W.; Valadan Tahbaz, S.; Valdez, P.R.; Venketasubramanian, N.; Vlassov, V.; Vu, G.T.; Vu, L.G.; Wang, Y-P.; Wimo, A.; Winkler, A.S.; Yadav, L.; Yahyazadeh Jabbari, S.H.; Yamagishi, K.; Yang, L.; Yano, Y.; Yonemoto, N.; Yu, C.; Yunusa, I.; Zadey, S.; Zastrozhin, M.S.; Zastrozhina, A.; Zhang, Z-J.; Murray, C.J.L.; Vos, T. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health, 2022, 7(2), e105-e125.
[http://dx.doi.org/10.1016/S2468-2667(21)00249-8] [PMID: 34998485]

Livingston, G.; Sommerlad, A.; Orgeta, V.; Costafreda, S.G.; Huntley, J.; Ames, D.; Ballard, C.; Banerjee, S.; Burns, A.; Cohen-Mansfield, J.; Cooper, C.; Fox, N.; Gitlin, L.N.; Howard, R.; Kales, H.C.; Larson, E.B.; Ritchie, K.; Rockwood, K.; Sampson, E.L.; Samus, Q.; Schneider, L.S.; Selbæk, G.; Teri, L.; Mukadam, N. Dementia prevention, intervention, and care. Lancet, 2017, 390(10113), 2673-2734.
[http://dx.doi.org/10.1016/S0140-6736(17)31363-6] [PMID: 28735855]

Ngandu, T.; Lehtisalo, J.; Solomon, A.; Levälahti, E.; Ahtiluoto, S.; Antikainen, R.; Bäckman, L.; Hänninen, T.; Jula, A.; Laatikainen, T.; Lindström, J.; Mangialasche, F.; Paajanen, T.; Pajala, S.; Peltonen, M.; Rauramaa, R.; Stigsdotter-Neely, A.; Strandberg, T.; Tuomilehto, J.; Soininen, H.; Kivipelto, M.A. 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet, 2015, 385(9984), 2255-2263.
[http://dx.doi.org/10.1016/S0140-6736(15)60461-5] [PMID: 25771249]

Cummings, J; Lee, G; Nahed, P; Kambar, MEZN; Zhong, K; Fonseca, J Alzheimer’s disease drug development pipeline. A&D Transl Res & Clin Interv 2022, 8(1)

Gribkoff, V.K.; Kaczmarek, L.K. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology, 2017, 120, 11-19.
[http://dx.doi.org/10.1016/j.neuropharm.2016.03.021] [PMID: 26979921]

Puentes-Díaz, N.; Chaparro, D.; Morales-Morales, D.; Flores-Gaspar, A.; Alí-Torres, J. Role of metal cations of copper, iron, and aluminum and multifunctional ligands in alzheimer’s disease: Experimental and computational insights. ACS Omega, 2023, 8(5), 4508-4526.
[http://dx.doi.org/10.1021/acsomega.2c06939] [PMID: 36777601]

Huang, H.C.; Jiang, Z.F. Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease. J. Alzheimers Dis., 2009, 16(1), 15-27.
[http://dx.doi.org/10.3233/JAD-2009-0960] [PMID: 19158417]

LaFerla, F.M. Pathways linking Aβ and tau pathologies. Biochem. Soc. Trans., 2010, 38(4), 993-995.
[http://dx.doi.org/10.1042/BST0380993] [PMID: 20658991]

Whitehouse, P.J. The cholinergic deficit in Alzheimer’s disease. J. Clin. Psychiatry, 1998, 59(Suppl. 13), 19-22.
[PMID: 9771826]

Lipton, S. The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res., 2005, 2(2), 155-165.
[http://dx.doi.org/10.2174/1567205053585846] [PMID: 15974913]

Ravona-Springer, R.; Davidson, M.; Noy, S. Is the distinction between Alzheimer’s disease and vascular dementia possible and relevant? Dialogues Clin. Neurosci., 2003, 5(1), 7-15.
[http://dx.doi.org/10.31887/DCNS.2003.5.1/rravonaspringer] [PMID: 22033677]

Hasnain, M.; Vieweg, W. Possible role of vascular risk factors in Alzheimer’s disease and vascular dementia. Curr. Pharm. Des., 2014, 20(38), 6007-6013.
[http://dx.doi.org/10.2174/1381612820666140314153440] [PMID: 24641219]

Attems, J.; Jellinger, K.A. The overlap between vascular disease and Alzheimer’s disease - lessons from pathology. BMC Med., 2014, 12(1), 206.
[http://dx.doi.org/10.1186/s12916-014-0206-2] [PMID: 25385447]

de Toledo Ferraz Alves, T.C.; Ferreira, L.K.; Wajngarten, M.; Busatto, G.F. Cardiac disorders as risk factors for Alzheimer’s disease. J. Alzheimers Dis., 2010, 20(3), 749-763.
[http://dx.doi.org/10.3233/JAD-2010-091561] [PMID: 20413875]

Midlife vascular risk factors and alzheimer’s disease: evidence from epidemiological studies. Available from: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad120802

Luchsinger, J.A. Adiposity, hyperinsulinemia, diabetes and Alzheimer’s disease. Eur. J. Pharmacol., 2008, 585(1), 119-129.
[http://dx.doi.org/10.1016/j.ejphar.2008.02.048] [PMID: 18384771]

Abdul-Hay, S.O.; Kang, D.; McBride, M.; Li, L.; Zhao, J.; Leissring, M.A. Deletion of insulindegrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance; PLoS ONE, 2011, 6(6), 20818.

Martinez, A.; Gil, C.; Perez, D.I. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer’s disease treatment. Int. J. Alzheimers Dis., 2011, 2011, 1-7.
[http://dx.doi.org/10.4061/2011/280502] [PMID: 21760986]

den Hoedt, S.; Crivelli, S.M.; Leijten, F.P.J.; Losen, M.; Stevens, J.A.A.; Mané-Damas, M.; de Vries, H.E.; Walter, J.; Mirzaian, M.; Sijbrands, E.J.G.; Aerts, J.M.F.G.; Verhoeven, A.J.M.; Martinez-Martinez, P.; Mulder, M.T. Effects of sex, age, and apolipoprotein e genotype on brain ceramides and sphingosine-1-phosphate in alzheimer’s disease and control mice. Front. Aging Neurosci., 2021, 13, 765252.
[http://dx.doi.org/10.3389/fnagi.2021.765252] [PMID: 34776936]

Liu, C.C.; Kanekiyo, T.; Xu, H.; Bu, G.; Bu, G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol., 2013, 9(2), 106-118.
[http://dx.doi.org/10.1038/nrneurol.2012.263] [PMID: 23296339]

Guo, T.; Zhang, D.; Zeng, Y.; Huang, T.Y.; Xu, H.; Zhao, Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol. Neurodegener., 2020, 15(1), 40.
[http://dx.doi.org/10.1186/s13024-020-00391-7] [PMID: 32677986]

Erickson, M.A.; Dohi, K.; Banks, W.A. Neuroinflammation: A common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation, 2012, 19(2), 121-130.
[http://dx.doi.org/10.1159/000330247] [PMID: 22248728]

Asanuma, M.; Nishibayashi-Asanuma, S.; Miyazaki, I.; Kohno, M.; Ogawa, N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem., 2001, 76(6), 1895-1904.
[http://dx.doi.org/10.1046/j.1471-4159.2001.00205.x] [PMID: 11259508]

Mallah, K.; Couch, C.; Borucki, D.M.; Toutonji, A.; Alshareef, M.; Tomlinson, S. Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Front. Immunol., 2020, 11, 2021.
[http://dx.doi.org/10.3389/fimmu.2020.02021] [PMID: 33013859]

Xu, J.; Patassini, S.; Begley, P.; Church, S.; Waldvogel, H.J.; Faull, R.L.M.; Unwin, R.D.; Cooper, G.J.S. Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer’s disease. Biochem. Biophys. Res. Commun., 2020, 527(3), 676-681.
[http://dx.doi.org/10.1016/j.bbrc.2020.05.015] [PMID: 32416962]

Cenini, G.; Voos, W. Mitochondria as potential targets in alzheimer disease therapy: An update. Front. Pharmacol., 2019, 10, 902.
[http://dx.doi.org/10.3389/fphar.2019.00902] [PMID: 31507410]

Gazit, N.; Vertkin, I.; Shapira, I.; Helm, M.; Slomowitz, E.; Sheiba, M.; Mor, Y.; Rizzoli, S.; Slutsky, I. IGF-1 Receptor differentially regulates spontaneous and evoked transmission via mitochondria at hippocampal synapses. Neuron, 2016, 89(3), 583-597.
[http://dx.doi.org/10.1016/j.neuron.2015.12.034] [PMID: 26804996]

Chang, X.L.; Tan, M.S.; Tan, L.; Yu, J.T. The Role of TDP-43 in Alzheimer’s Disease. Mol. Neurobiol., 2016, 53(5), 3349-3359.
[http://dx.doi.org/10.1007/s12035-015-9264-5] [PMID: 26081142]

Chun, H.; Lee, C.J. Reactive astrocytes in Alzheimer’s disease: A double-edged sword. Neurosci. Res., 2018, 126, 44-52.
[http://dx.doi.org/10.1016/j.neures.2017.11.012] [PMID: 29225140]

Wang, X.P.; Ye, P.; Lv, J.; Zhou, L.; Qian, Z.Y.; Huang, Y.J.; Mu, Z.H.; Wang, X.; Liu, X.; Wan, Q.; Yang, Z.H.; Wang, F.; Zou, Y.Y. Expression changes of NMDA and AMPA receptor subunits in the hippocampus in rats with diabetes induced by streptozotocin coupled with memory impairment. Neurochem. Res., 2019, 44(4), 978-993.
[http://dx.doi.org/10.1007/s11064-019-02733-4] [PMID: 30747310]

Muraoka, S.; Jedrychowski, M.P.; Yanamandra, K.; Ikezu, S.; Gygi, S.P.; Ikezu, T. Proteomic profiling of extracellular vesicles derived from cerebrospinal fluid of alzheimer’s disease patients: A pilot study. Cells, 2020, 9(9), 1959.
[http://dx.doi.org/10.3390/cells9091959] [PMID: 32854315]

Peyressatre, M.; Arama, D.P.; Laure, A.; González-Vera, J.A.; Pellerano, M.; Masurier, N.; Lisowski, V.; Morris, M.C. Identification of quinazolinone analogs targeting CDK5 kinase activity and glioblastoma cell proliferation. Front Chem., 2020, 8, 691.
[http://dx.doi.org/10.3389/fchem.2020.00691] [PMID: 32974274]

Duncan, R.; Song, B.; Koulen, P. Presenilins as drug targets for alzheimer’s disease—recent insights from cell biology and electrophysiology as novel opportunities in drug development. Int. J. Mol. Sci., 2018, 19(6), 1621.
[http://dx.doi.org/10.3390/ijms19061621] [PMID: 29857474]

Miraj, S. Rafieian-Kopaei; Kiani, S. Melissa officinalis L: A review study with an antioxidant prospective. J. Evid. Based Complementary Altern. Med., 2017, 22(3), 385-394.
[http://dx.doi.org/10.1177/2156587216663433] [PMID: 27620926]

Sepand, M.R.; Soodi, M.; Hajimehdipoor, H.; Soleimani, M.; Sahraei, E. Comparison of neuroprotective effects of melissa officinalis total extract and its acidic and non-acidic fractions against a β-induced toxicity. Iran. J. Pharm. Res., 2013, 12(2), 415-423.
[PMID: 24250617]

Jeong, H.Y.; Kim, J.Y.; Lee, H.K.; Ha, D.T.; Song, K.S.; Bae, K.; Seong, Y.H. Leaf and stem of Vitis amurensis and its active components protect against amyloid β protein (25–35)-induced neurotoxicity. Arch. Pharm. Res., 2010, 33(10), 1655-1664.
[http://dx.doi.org/10.1007/s12272-010-1015-6] [PMID: 21052941]

Stanciu, G.D.; Luca, A.; Rusu, R.N.; Bild, V.; Beschea Chiriac, S.I.; Solcan, C.; Bild, W.; Ababei, D.C. Alzheimer’s disease pharmacotherapy in relation to cholinergic system involvement. Biomolecules, 2019, 10(1), 40.
[http://dx.doi.org/10.3390/biom10010040] [PMID: 31888102]

Akram, M.; Nawaz, A. Effects of medicinal plants on Alzheimer’s disease and memory deficits. Neural Regen. Res., 2017, 12(4), 660-670.
[http://dx.doi.org/10.4103/1673-5374.205108] [PMID: 28553349]

Mahrous, R.S.R.; Ghareeb, D.A.; Fathy, H.M.; Abu, E.L. Khair, R.M.; Abdallah, The protective effect of egyptian withania somnifera against alzeheimer’s. Med. Aromat. Plants, 2017, 6(2)
[http://dx.doi.org/10.4172/2167-0412.1000285]

Abdul Manap, A.S.; Vijayabalan, S.; Madhavan, P.; Chia, Y.Y.; Arya, A.; Wong, E.H.; Rizwan, F.; Bindal, U.; Koshy, S. Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. Drug Target Insights, 2019, 13.
[http://dx.doi.org/10.1177/1177392819866412] [PMID: 31391778]

Bastianetto, S.; Zheng, W.H.; Quirion, R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J. Neurochem., 2000, 74(6), 2268-2277.
[http://dx.doi.org/10.1046/j.1471-4159.2000.0742268.x] [PMID: 10820186]

Sandur, S.K.; Pandey, M.K.; Sung, B.; Ahn, K.S.; Murakami, A.; Sethi, G.; Limtrakul, P.; Badmaev, V.; Aggarwal, B.B. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis, 2007, 28(8), 1765-1773.
[http://dx.doi.org/10.1093/carcin/bgm123] [PMID: 17522064]

Karunaweera, N.; Raju, R.; Gyengesi, E.; Münch, G. Plant polyphenols as inhibitors of NF-κB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer’s disease? Front. Mol. Neurosci., 2015, 8, 24.
[http://dx.doi.org/10.3389/fnmol.2015.00024] [PMID: 26136655]

Wahab, S.; Annadurai, S.; Abullais, S.S.; Das, G.; Ahmad, W.; Ahmad, M.F.; Kandasamy, G.; Vasudevan, R.; Ali, M.S.; Amir, M. Glycyrrhiza glabra (Licorice): A comprehensive review on its phytochemistry, biological activities, clinical evidence and toxicology. Plants, 2021, 10(12), 2751.
[http://dx.doi.org/10.3390/plants10122751] [PMID: 34961221]

Cho, M.J.; Kim, J.H.; Park, C.H.; Lee, A.Y.; Shin, Y.S.; Lee, J.H.; Park, C.G.; Cho, E.J. Comparison of the effect of three licorice varieties on cognitive improvement via an amelioration of neuroinflammation in lipopolysaccharide-induced mice. Nutr. Res. Pract., 2018, 12(3), 191-198.
[http://dx.doi.org/10.4162/nrp.2018.12.3.191] [PMID: 29854324]

Song, J.H.; Lee, J.W.; Shim, B.; Lee, C.Y.; Choi, S.; Kang, C.; Sohn, N.W.; Shin, J.W. Glycyrrhizin alleviates neuroinflammation and memory deficit induced by systemic lipopolysaccharide treatment in mice. Molecules, 2013, 18(12), 15788-15803.
[http://dx.doi.org/10.3390/molecules181215788] [PMID: 24352029]

Guo, J.; Yang, C.; Yang, J.; Yao, Y. Glycyrrhizic acid ameliorates cognitive impairment in a rat model of vascular dementia associated with oxidative damage and inhibition of voltage-gated sodium channels. CNS Neurol. Disord. Drug Targets, 2016, 15(8), 1001-1008.
[http://dx.doi.org/10.2174/1871527315666160527163526] [PMID: 27238153]

Shekarian, M.; Komaki, A.; Shahidi, S.; Sarihi, A.; Salehi, I.; Raoufi, S. The protective and therapeutic effects of vinpocetine, a PDE1 inhibitor, on oxidative stress and learning and memory impairment induced by an intracerebroventricular (ICV) injection of amyloid beta (aβ) peptide. Behav. Brain Res., 2020, 383, 112512.
[http://dx.doi.org/10.1016/j.bbr.2020.112512] [PMID: 31991177]

Szatmári, S.Z.; Whitehouse, P.J. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev., 2003, 2003(1), CD003119.
[PMID: 12535455]

Zhang, B.; Li, Q.; Chu, X.; Sun, S.; Chen, S. Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer’s disease. Transl. Neurodegener., 2016, 5(1), 21.
[http://dx.doi.org/10.1186/s40035-016-0068-y] [PMID: 27933142]

Zhang, B.; Wang, Y.; Li, H.; Xiong, R.; Zhao, Z.; Chu, X.; Li, Q.; Sun, S.; Chen, S. Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models. Drug Des. Devel. Ther., 2016, 10, 1335-1343.
[PMID: 27103787]

Zhang, L.; Yu, H.; Zhao, X.; Lin, X.; Tan, C.; Cao, G.; Wang, Z. Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells. Neurochem. Int., 2010, 57(5), 547-555.
[http://dx.doi.org/10.1016/j.neuint.2010.06.021] [PMID: 20615444]

Li, Y.; Wu, J.; Shi, R.; Li, N.; Xu, Z.; Sun, M. Antioxidative effects of rhodiola genus: Phytochemistry and pharmacological mechanisms against the diseases. Curr. Top. Med. Chem., 2017, 17(15), 1692-1708.
[http://dx.doi.org/10.2174/1568026617666161116141334] [PMID: 27848900]

Yan, Z.Q.; Chen, J.; Xing, G.X.; Huang, J.G.; Hou, X.H.; Zhang, Y. Salidroside prevents cognitive impairment induced by chronic cerebral hypoperfusion in rats. J. Int. Med. Res., 2015, 43(3), 402-411.
[http://dx.doi.org/10.1177/0300060514566648] [PMID: 25858674]

Zhou, Q.; Yin, Z.P.; Ma, L.; Zhao, W.; Hao, H.W.; Li, H.L. Free radical-scavenging activities of oligomeric proanthocyanidin from Rhodiola rosea L. and its antioxidant effects in vivo. Nat. Prod. Res., 2014, 28(24), 2301-2303.
[http://dx.doi.org/10.1080/14786419.2014.921786] [PMID: 24896611]

de Macedo, L.M.; Santos, É.M.; Militão, L.; Tundisi, L.L.; Ataide, J.A.; Souto, E.B.; Mazzola, P.G. Rosemary (Rosmarinus officinalis L., syn Salvia rosmarinus Spenn.) and Its Topical Applications: A Review. Plants, 2020, 9(5), 651.
[http://dx.doi.org/10.3390/plants9050651] [PMID: 32455585]

Lamaison, J.L.; Petitjean-Freytet, C.; Carnat, A. [Rosmarinic acid, total hydroxycinnamic derivatives and antioxidant activity of Apiaceae, Borraginaceae and Lamiceae medicinals]. Ann. Pharm. Fr., 1990, 48(2), 103-108. [Rosmarinic acid, total hydroxycinnamic derivatives and antioxidant activity of Apiaceae, Borraginaceae and Lamiaceae medicinals].
[PMID: 2291599]

Orhan, I. Küpeli, E.; Şener, B.; Yesilada, E. Appraisal of anti-inflammatory potential of the clubmoss, Lycopodium clavatum L. J. Ethnopharmacol., 2007, 109(1), 146-150.
[http://dx.doi.org/10.1016/j.jep.2006.07.018] [PMID: 16962272]

Snow, A.D.; Castillo, G.M.; Nguyen, B.P.; Choi, P.Y.; Cummings, J.A.; Cam, J.; Hu, Q.; Lake, T.; Pan, W.; Kastin, A.J.; Kirschner, D.A.; Wood, S.G.; Rockenstein, E.; Masliah, E.; Lorimer, S.; Tanzi, R.E.; Larsen, L. The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. Sci. Rep., 2019, 9(1), 561.
[http://dx.doi.org/10.1038/s41598-019-38645-0] [PMID: 30728442]

Liu, Q.F.; Jeong, H.; Lee, J.H.; Hong, Y.K.; Oh, Y.; Kim, Y.M.; Suh, Y.S.; Bang, S.; Yun, H.S.; Lee, K.; Cho, S.M.; Lee, S.B.; Jeon, S.; Chin, Y.W.; Koo, B.S.; Cho, K.S. Coriandrum sativum Suppresses Aβ42-Induced ROS Increases, glial cell proliferation, and ERK Activation. Am. J. Chin. Med., 2016, 44(7), 1325-1347.
[http://dx.doi.org/10.1142/S0192415X16500749] [PMID: 27776428]

Sun, Y.; Yang, Y.; Liu, S.; Yang, S.; Chen, C.; Lin, M.; Zeng, Q.; Long, J.; Yao, J.; Yi, F.; Meng, L.; Ai, Q.; Chen, N. New therapeutic approaches to and mechanisms of ginsenoside rg1 against neurological diseases. Cells, 2022, 11(16), 2529.
[http://dx.doi.org/10.3390/cells11162529] [PMID: 36010610]

Kim, J.H.; Yi, Y.S.; Kim, M.Y.; Cho, J.Y. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J. Ginseng Res., 2017, 41(4), 435-443.
[http://dx.doi.org/10.1016/j.jgr.2016.08.004] [PMID: 29021688]

Arendash, G.W.; Mori, T.; Cao, C.; Mamcarz, M.; Runfeldt, M.; Dickson, A.; Rezai-Zadeh, K.; Tan, J.; Citron, B.A.; Lin, X.; Echeverria, V.; Potter, H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer’s disease mice. J. Alzheimers Dis., 2009, 17(3), 661-680.
[http://dx.doi.org/10.3233/JAD-2009-1087] [PMID: 19581722]

Lee, Y.K.; Yuk, D.Y.; Kim, T.I.; Kim, Y.H.; Kim, K.T.; Kim, K.H.; Lee, B.J.; Nam, S.Y.; Hong, J.T. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. J. Nat. Med., 2009, 63(3), 274-282.
[http://dx.doi.org/10.1007/s11418-009-0330-z] [PMID: 19343477]

D’Onofrio, G.; Nabavi, S.M.; Sancarlo, D.; Greco, A.; Pieretti, S. Crocus Sativus L. (Saffron) in Alzheimer’s disease treatment: Bioactive effects on cognitive impairment. Curr. Neuropharmacol., 2021, 19(9), 1606-1616.
[PMID: 33441068]

Rubio, J.; Dang, H.; Gong, M.; Liu, X.; Chen, S.; Gonzales, G.F. Aqueous and hydroalcoholic extracts of Black Maca (Lepidium meyenii) improve scopolamine-induced memory impairment in mice. Food Chem. Toxicol., 2007, 45(10), 1882-1890.
[http://dx.doi.org/10.1016/j.fct.2007.04.002] [PMID: 17543435]

Saxena, V.; Ahmad, H.; Gupta, R. Memory enhancing effects of Ficus carica leaves in hexane extract on interoceptive behavioral models. Asian J. Pharm. Clin. Res., 2013, 6, 109-113.

Dwivedi, V.; Maurya, H. A comprehensive overview of celastrus paniculatus seed oil intended for the management of human ailments. Indian Journal of Pharmaceutical and Biological Research, 2018, 6(2), 37-42.
[http://dx.doi.org/10.30750/ijpbr.6.2.7]

Badrul, A.; Ekramul, H. Anti-Alzheimer and antioxidant activity of celastrus paniculatus seed. Indian J. Pharm. Sci., 2011, 7(1), 49-56.

Sharma, R.; Singla, R.K.; Banerjee, S.; Sinha, B.; Shen, B.; Sharma, R. Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies. Neurosci. Biobehav. Rev., 2022, 140, 104795.
[http://dx.doi.org/10.1016/j.neubiorev.2022.104795] [PMID: 35878793]

Purnima, M.B.; Kothiyal, P. A review article on phytochemistry and pharmacological profiles of Nardostachys jatamansi DC-medicinal herb. J. Pharmacogn. Phytochem., 2015, 3(5), 102-106.

Gray, N.E.; Zweig, J.A.; Caruso, M.; Zhu, J.Y.; Wright, K.M.; Quinn, J.F.; Soumyanath, A. Centella asiatica attenuates hippocampal mitochondrial dysfunction and improves memory and executive function in β-amyloid overexpressing mice. Mol. Cell. Neurosci., 2018, 93, 1-9.
[http://dx.doi.org/10.1016/j.mcn.2018.09.002] [PMID: 30253196]

Choi, S.J.; Lee, J.H.; Heo, H.J.; Cho, H.Y.; Kim, H.K.; Kim, C.J.; Kim, M.O.; Suh, S.H.; Shin, D.H. Punica granatum protects against oxidative stress in PC12 cells and oxidative stress-induced Alzheimer’s symptoms in mice. J. Med. Food, 2011, 14(7-8), 695-701.

Sathya, S.; Amarasinghe, N.R.; Jayasinghe, L.; Araya, H.; Fujimoto, Y. Enzyme inhibitors from the aril of Myristica fragrans. S. Afr. J. Bot., 2020, 130, 172-176.
[http://dx.doi.org/10.1016/j.sajb.2019.12.020]

Beheshti, S.; Shahmoradi, B. Therapeutic effect of Melissa officinalis in an amyloid-β rat model of Alzheimer’s disease. Journal of Herbmed Pharmacology, 2018, 7(3), 193-199.
[http://dx.doi.org/10.15171/jhp.2018.31]

Mohammad Sadeghi, H.; Adeli, I.; Mousavi, T.; Daniali, M.; Nikfar, S.; Abdollahi, M. Drug repurposing for the management of depression: Where do we stand currently? Life, 2021, 11(8), 774.
[http://dx.doi.org/10.3390/life11080774] [PMID: 34440518]

Kandiah, N.; Pai, M.C.; Senanarong, V.; Looi, I.; Ampil, E.; Park, K.W.; Karanam, A.K.; Christopher, S. Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clin. Interv. Aging, 2017, 12, 697-707.
[http://dx.doi.org/10.2147/CIA.S129145] [PMID: 28458525]

Johnson, J.; Kotermanski, S. Mechanism of action of memantine. Curr. Opin. Pharmacol., 2006, 6(1), 61-67.
[http://dx.doi.org/10.1016/j.coph.2005.09.007] [PMID: 16368266]

Breijyeh, Z.; Karaman, R. Comprehensive review on alzheimer’s disease: Causes and treatment. Molecules, 2020, 25(24), 5789.
[http://dx.doi.org/10.3390/molecules25245789] [PMID: 33302541]

Zhang, K.; Yamaki, V.N.; Wei, Z.; Zheng, Y.; Cai, X. Differential regulation of GluA1 expression by ketamine and memantine. Behav. Brain Res., 2017, 316, 152-159.
[http://dx.doi.org/10.1016/j.bbr.2016.09.002] [PMID: 27599619]

Kumar, S. Memantine: Pharmacological properties and clinical uses. Neurol. India, 2004, 52(3), 307-309.
[PMID: 15472417]

Flores-Clemente, C.; Nicolás-Vázquez, M.I.; Mera Jiménez, E.; Hernández-Rodríguez, M. Inhibition of astrocytic histamine n-methyltransferase as a possible target for the treatment of alzheimer’s disease. Biomolecules, 2021, 11(10), 1408.
[http://dx.doi.org/10.3390/biom11101408] [PMID: 34680041]

Colović, M.B.; Krstić, D.Z.; Lazarević,-Pašti, T.D.; Bondžić, A.M.; Vasić, V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol., 2013, 11(3), 315-335.
[http://dx.doi.org/10.2174/1570159X11311030006] [PMID: 24179466]

Bohnen, N.I.; Kaufer, D.I.; Hendrickson, R.; Ivanco, L.S.; Lopresti, B.J.; Koeppe, R.A.; Meltzer, C.C.; Constantine, G.; Davis, J.G.; Mathis, C.A.; Dekosky, S.T.; Moore, R.Y. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 2005, 76(3), 315-319.
[http://dx.doi.org/10.1136/jnnp.2004.038729] [PMID: 15716518]

Homma, A.; Atarashi, H.; Kubota, N.; Nakai, K.; Takase, T. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in japanese patients with severe alzheimer’s disease: A randomized, double-blind trial. J. Alzheimers Dis., 2016, 52(1), 345-357.
[http://dx.doi.org/10.3233/JAD-151149] [PMID: 26967222]

Bajpai, S.; Tripathi, M.; Pandey, R.M.; Dey, A.B.; Nehra, A. Development and validation of cognitive training intervention for alzheimer’s disease (cti-ad): A picture-based interventional program. Dementia, 2020, 19(4), 1203-1219.
[http://dx.doi.org/10.1177/1471301218797043] [PMID: 30180764]

Nousia, A.; Siokas, V.; Aretouli, E.; Messinis, L.; Aloizou, A.M.; Martzoukou, M.; Karala, M.; Koumpoulis, C.; Nasios, G.; Dardiotis, E. Beneficial effect of multidomain cognitive training on the neuropsychological performance of patients with early-stage alzheimer’s disease. Neural Plast., 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/2845176] [PMID: 30123243]

Clements-Cortes, A.; Ahonen, H.; Evans, M.; Freedman, M.; Bartel, L. Short-term effects of rhythmic sensory stimulation in alzheimer’s disease: An exploratory pilot study. J. Alzheimers Dis., 2016, 52(2), 651-660.
[http://dx.doi.org/10.3233/JAD-160081] [PMID: 27031491]

Clare, L.; Wilson, B.A.; Carter, G.; Roth, I.; Hodges, J.R. Relearning face-name associations in early Alzheimer’s disease. Neuropsychology, 2002, 16(4), 538-547.
[http://dx.doi.org/10.1037/0894-4105.16.4.538] [PMID: 12382992]

Burns, J.M.; Cronk, B.B.; Anderson, H.S.; Donnelly, J.E.; Thomas, G.P.; Harsha, A.; Brooks, W.M.; Swerdlow, R.H. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology, 2008, 71(3), 210-216.
[http://dx.doi.org/10.1212/01.wnl.0000317094.86209.cb] [PMID: 18625967]

Bahar-Fuchs, A.; Clare, L.; Woods, B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Libr., 2013, 2013(6), CD003260.
[http://dx.doi.org/10.1002/14651858.CD003260.pub2] [PMID: 23740535]

Erickson, K.I.; Voss, M.W.; Prakash, R.S.; Basak, C.; Szabo, A.; Chaddock, L.; Kim, J.S.; Heo, S.; Alves, H.; White, S.M.; Wojcicki, T.R.; Mailey, E.; Vieira, V.J.; Martin, S.A.; Pence, B.D.; Woods, J.A.; McAuley, E.; Kramer, A.F. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci., 2011, 108(7), 3017-3022.
[http://dx.doi.org/10.1073/pnas.1015950108] [PMID: 21282661]

Liu, P.Z.; Nusslock, R. Exercise-Mediated Neurogenesis in the Hippocampus via BDNF. Front. Neurosci., 2018, 12, 52.
[http://dx.doi.org/10.3389/fnins.2018.00052] [PMID: 29467613]

Noreik, M.; Kuhn, J.; Hardenacke, K.; Lenartz, D.; Bauer, A.; Bührle, C.P.; Häussermann, P.; Hellmich, M.; Klosterkötter, J.; Wiltfang, J.; Maarouf, M.; Freund, H.J.; Visser-Vandewalle, V.; Sturm, V.; Schulz, R.J. Changes in nutritional status after deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s disease — Results of a phase I study. J. Nutr. Health Aging, 2015, 19(8), 812-818.
[http://dx.doi.org/10.1007/s12603-015-0595-8] [PMID: 26412285]

Stagg, C.J.; Nitsche, M.A. Physiological basis of transcranial direct current stimulation. Neuroscientist, 2011, 17(1), 37-53.
[http://dx.doi.org/10.1177/1073858410386614] [PMID: 21343407]

Bauer, P.R.; Kalitzin, S.; Zijlmans, M.; Sander, J.W.; Visser, G.H. Cortical excitability as a potential clinical marker of epilepsy: A review of the clinical application of transcranial magnetic stimulation. Int. J. Neural Syst., 2014, 24(2), 1430001.
[http://dx.doi.org/10.1142/S0129065714300010] [PMID: 24475894]

Legon, W.; Ai, L.; Bansal, P.; Mueller, J.K. Neuromodulation with single-element transcranial focused ultrasound in human thalamus. Hum. Brain Mapp., 2018, 39(5), 1995-2006.
[http://dx.doi.org/10.1002/hbm.23981] [PMID: 29380485]

Huang, Y.Z.; Edwards, M.J.; Rounis, E.; Bhatia, K.P.; Rothwell, J.C. Theta burst stimulation of the human motor cortex. Neuron, 2005, 45(2), 201-206.
[http://dx.doi.org/10.1016/j.neuron.2004.12.033] [PMID: 15664172]

Soininen, H.; Solomon, A.; Visser, P.J.; Hendrix, S.B.; Blennow, K.; Kivipelto, M.; Hartmann, T.; Hallikainen, I.; Hallikainen, M.; Helisalmi, S.; Lappalainen, T.; Liu, Y.; Paajanen, T.; Wahlund, L-O.; Freund-Levi, Y.; Andreasen, N.; Hagman, G.; Lindblom, S.; Fassbender, K.; Riemenschneider, M.; Grimm, M.O.W.; Klees-Rollmann, A.; Luley, M.; Lyros, E.; Schomburg, R.; Kennel, J.; Ramelli, D.; Frölich, L.; Hausner, L.; Laske, C.; Leyhe, T.; Mychajliw, C.; Koehler, N.; Schiekofer, S.; Klünemann, H.; Schröder, J.; Lütjohann, D.; Scheltens, P.; van Rossum, I.; Scheltens, N.; Bertens, D.; ten Kate, M.; Barkhof, F.; Henselmans, J.M.L.; Roks, G.; van Hees, A.M.J.; Ellison, N. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): A randomised, double-blind, controlled trial. Lancet Neurol., 2017, 16(12), 965-975.
[http://dx.doi.org/10.1016/S1474-4422(17)30332-0] [PMID: 29097166]

Suzuki, H.; Yamashiro, D.; Ogawa, S.; Kobayashi, M.; Cho, D.; Iizuka, A.; Tsukamoto-Yasui, M.; Takada, M.; Isokawa, M.; Nagao, K.; Fujiwara, Y. Intake of seven essential amino acids improves cognitive function and psychological and social function in middle-aged and older adults: A double-blind, randomized, placebo-controlled trial. Front. Nutr., 2020, 7, 586166.
[http://dx.doi.org/10.3389/fnut.2020.586166] [PMID: 33324669]

Yulug, B.; Altay, O.; Li, X.; Hanoglu, L.; Cankaya, S.; Lam, S.; Velioglu, H.A.; Yang, H.; Coskun, E.; Idil, E.; Nogaylar, R.; Ozsimsek, A.; Bayram, C.; Bolat, I.; Oner, S.; Tozlu, O.O.; Arslan, M.E.; Hacimuftuoglu, A.; Yildirim, S.; Arif, M.; Shoaie, S.; Zhang, C.; Nielsen, J.; Turkez, H.; Borén, J.; Uhlén, M.; Mardinoglu, A. Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: A randomised, double-blinded, placebo-controlled phase-II trial. Transl. Neurodegener., 2023, 12(1), 4.
[http://dx.doi.org/10.1186/s40035-023-00336-2] [PMID: 36703196]

Schmitt, B.; Bernhardt, T.; Moeller, H.J.; Heuser, I.; Frölich, L. Combination therapy in Alzheimer’s disease: A review of current evidence. CNS Drugs, 2004, 18(13), 827-844.
[http://dx.doi.org/10.2165/00023210-200418130-00001] [PMID: 15521788]

Weiner, M.W.; Sadowsky, C.; Saxton, J.; Hofbauer, R.K.; Graham, S.M.; Yu, S.Y.; Li, S.; Hsu, H.A.; Suhy, J.; Fridman, M.; Perhach, J.L. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease. Alzheimers Dement., 2011, 7(4), 425-435.
[http://dx.doi.org/10.1016/j.jalz.2010.09.003] [PMID: 21646051]

Choi, S.H.; Park, K.W.; Na, D.L.; Han, H.J.; Kim, E.J.; Shim, Y.S.; Lee, J.H. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study. Curr. Med. Res. Opin., 2011, 27(7), 1375-1383.
[http://dx.doi.org/10.1185/03007995.2011.582484] [PMID: 21561398]

Farlow, M.R.; Alva, G.; Meng, X.; Olin, J.T. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr. Med. Res. Opin., 2010, 26(2), 263-269.
[http://dx.doi.org/10.1185/03007990903434914] [PMID: 19929593]

Lopez, O.L.; Becker, J.T.; Wahed, A.S.; Saxton, J.; Sweet, R.A.; Wolk, D.A.; Klunk, W.; DeKosky, S.T. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry, 2009, 80(6), 600-607.
[http://dx.doi.org/10.1136/jnnp.2008.158964] [PMID: 19204022]

Riepe, M.W.; Adler, G.; Ibach, B.; Weinkauf, B.; Tracik, F.; Gunay, I. Domain-specific improvement of cognition on memantine in patients with Alzheimer’s disease treated with rivastigmine. Dement. Geriatr. Cogn. Disord., 2007, 23(5), 301-306.
[http://dx.doi.org/10.1159/000100875] [PMID: 17356273]

Thomas, S.J.; Grossberg, G.T. Memantine: A review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin. Interv. Aging, 2009, 4, 367-377.
[PMID: 19851512]

Porsteinsson, A.; Grossberg, G.; Mintzer, J.; Olin, J. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res., 2008, 5(1), 83-89.
[http://dx.doi.org/10.2174/156720508783884576] [PMID: 18288936]

Schmitt, F.A.; van Dyck, C.H.; Wichems, C.H.; Olin, J.T. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis. Assoc. Disord., 2006, 20(4), 255-262.
[http://dx.doi.org/10.1097/01.wad.0000213860.35355.d4] [PMID: 17132970]

Atri, A.; Shaughnessy, L.W.; Locascio, J.J.; Growdon, J.H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2008, 22(3), 209-221.
[http://dx.doi.org/10.1097/WAD.0b013e31816653bc] [PMID: 18580597]

Dantoine, T.; Auriacombe, S.; Sarazin, M.; Becker, H.; Pere, J-J.; Bourdeix, I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract., 2006, 60(1), 110-118.
[http://dx.doi.org/10.1111/j.1368-5031.2005.00769.x] [PMID: 16409439]

Takada-Takatori, Y.; Kume, T.; Sugimoto, M.; Katsuki, H.; Sugimoto, H.; Akaike, A. Acetylcholinesterase inhibitors used in treatment of Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology, 2006, 51(3), 474-486.
[http://dx.doi.org/10.1016/j.neuropharm.2006.04.007] [PMID: 16762377]

Serrano-Pozo, A.; William, C.M.; Ferrer, I.; Uro-Coste, E.; Delisle, M.B.; Maurage, C.A.; Hock, C.; Nitsch, R.M.; Masliah, E.; Growdon, J.H.; Frosch, M.P.; Hyman, B.T. Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology. Brain, 2010, 133(5), 1312-1327.
[http://dx.doi.org/10.1093/brain/awq056] [PMID: 20360050]

Peña-Altamira, E.; Prati, F.; Massenzio, F.; Virgili, M.; Contestabile, A.; Bolognesi, M.L.; Monti, B. Changing paradigm to target microglia in neurodegenerative diseases: From anti-inflammatory strategy to active immunomodulation. Expert Opin. Ther. Targets, 2016, 20(5), 627-640.
[http://dx.doi.org/10.1517/14728222.2016.1121237] [PMID: 26568363]

Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B.H. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J. Mol. Neurosci., 2009, 37(2), 135-145.
[http://dx.doi.org/10.1007/s12031-008-9139-6] [PMID: 18751929]

Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C.L.; Targum, S.; Bush, A.I.; Murdoch, R.; Wilson, J.; Ritchie, C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol., 2008, 7(9), 779-786.
[http://dx.doi.org/10.1016/S1474-4422(08)70167-4] [PMID: 18672400]

Mohs, R.C.; Shiovitz, T.M.; Tariot, P.N.; Porsteinsson, A.P.; Baker, K.D.; Feldman, P.D. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am. J. Geriatr. Psychiatry, 2009, 17(9), 752-759.
[http://dx.doi.org/10.1097/JGP.0b013e3181aad585] [PMID: 19700948]

Alvarez, X.A.; Cacabelos, R.; Sampedro, C.; Couceiro, V.; Aleixandre, M.; Vargas, M.; Linares, C.; Granizo, E.; García-Fantini, M.; Baurecht, W.; Doppler, E.; Moessler, H. Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr. Alzheimer Res., 2011, 8(5), 583-591.
[http://dx.doi.org/10.2174/156720511796391863] [PMID: 21679156]

Uddin, MS Kabir, MT Oxidative stress in Alzheimer's disease: molecular hallmarks of underlying vulnerability. Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease: Nonpharmacological Therapies for Alzheimer's Disease, 2019, 91-115.
[http://dx.doi.org/10.1007/978-981-13-9636-6_5]

Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; Schneider, L.S.; Thal, L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med., 1997, 336(17), 1216-1222.
[http://dx.doi.org/10.1056/NEJM199704243361704] [PMID: 9110909]

Aisen, P.S.; Schneider, L.S.; Sano, M.; Diaz-Arrastia, R.; van Dyck, C.H.; Weiner, M.F.; Bottiglieri, T.; Jin, S.; Stokes, K.T.; Thomas, R.G.; Thal, L.J. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA, 2008, 300(15), 1774-1783.
[http://dx.doi.org/10.1001/jama.300.15.1774] [PMID: 18854539]

Freund-Levi, Y.; Eriksdotter-Jönhagen, M.; Cederholm, T.; Basun, H.; Faxén-Irving, G.; Garlind, A.; Vedin, I.; Vessby, B.; Wahlund, L.O.; Palmblad, J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol., 2006, 63(10), 1402-1408.
[http://dx.doi.org/10.1001/archneur.63.10.1402] [PMID: 17030655]

Moore, A.H.; Bigbee, M.J.; Boynton, G.E.; Wakeham, C.M.; Rosenheim, H.M.; Staral, C.J.; Morrissey, J.L.; Hund, A.K. Non-Steroidal anti-inflammatory drugs in alzheimer’s disease and parkinson’s disease: Reconsidering the role of neuroinflammation. Pharmaceuticals, 2010, 3(6), 1812-1841.
[http://dx.doi.org/10.3390/ph3061812] [PMID: 27713331]

Pasqualetti, P.; Bonomini, C.; Dal Forno, G.; Paulon, L.; Sinforiani, E.; Marra, C.; Zanetti, O.; Maria Rossini, P. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin. Exp. Res., 2009, 21(2), 102-110.
[http://dx.doi.org/10.1007/BF03325217] [PMID: 19448381]

Soininen, H.; West, C.; Robbins, J.; Niculescu, L. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord., 2007, 23(1), 8-21.
[http://dx.doi.org/10.1159/000096588] [PMID: 17068392]

Aisen, P.S.; Schafer, K.A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K.L.; Farlow, M.R.; Jin, S.; Thomas, R.G.; Thal, L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA, 2003, 289(21), 2819-2826.
[http://dx.doi.org/10.1001/jama.289.21.2819] [PMID: 12783912]

Zhong, K.L.; Chen, F.; Hong, H.; Ke, X.; Lv, Y.G.; Tang, S.S.; Zhu, Y.B. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer’s Disease. Metab. Brain Dis., 2018, 33(4), 1009-1018.
[http://dx.doi.org/10.1007/s11011-018-0227-1] [PMID: 29626315]

Plastino, M.; Fava, A.; Pirritano, D.; Cotronei, P.; Sacco, N.; Sperlì, T.; Spanò, A.; Gallo, D.; Mungari, P.; Consoli, D.; Bosco, D. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and Diabetes Mellitus type-2. J. Neurol. Sci., 2010, 288(1-2), 112-116.
[http://dx.doi.org/10.1016/j.jns.2009.09.022] [PMID: 19836029]

Patel, L.; Grossberg, G.T. Combination therapy for Alzheimer’s disease. Drugs Aging, 2011, 28(7), 539-546.
[http://dx.doi.org/10.2165/11591860-000000000-00000] [PMID: 21721598]

Kabir, M.T.; Uddin, M.S.; Mamun, A.A.; Jeandet, P.; Aleya, L.; Mansouri, R.A.; Ashraf, G.M.; Mathew, B.; Bin-Jumah, M.N.; Abdel-Daim, M.M. Combination Drug Therapy for the Management of Alzheimer’s Disease. Int. J. Mol. Sci., 2020, 21(9), 3272.
[http://dx.doi.org/10.3390/ijms21093272] [PMID: 32380758]

Rajesh, R; Pallavi, J; Padmapriya, M; Deena, J.T Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia. WJP world. Journal of. Psychiatry, 2020, 10(4), 29-33.